PURPOSE: To determine the relative contributions of patient, disease and therapy specific factors on neurocognitive outcome of brain tumor patients. PATIENTS AND METHODS: Seventy-nine patients (mean age = 41.1 years; range: 17-75 years; 54% male, 46% female) with glioblastoma multiforme (37%), anaplastic astrocytoma (17%), low grade astrocytoma (13%), and oligodendroglioma (10%) predominantly in the frontal regions (45%) were evaluated in an outpatient neuro-oncology clinic. A neuropsychological test battery emphasized elements of attention/concentration. Multiple regression analyses determined relationships between functional outcomes and demographic and clinical predictors. RESULTS: Key predictors of neurocognitive functioning included age of the patient (36-59 years, p < 0.01; >/= 60 years, p < 0.05) and frontal region tumor location (p < 0.01). As expected, older patients did not perform as well as younger patients in absolute terms on neuropsychological tests; decrements persisted when comparisons were based on age-standardized versions of neurocognitive outcomes. Major depressive disorder was marginally associated with outcomes, while surgical interventions and radiotherapy did not show strong associations with test performances. CONCLUSIONS: Primary malignant brain disease was found to be less negative on neurocognitive outcomes for younger than for either middle-aged or older patients. Treatments were not as predictive of neurocognitive outcomes as age. No single test outcome measure was as sensitive to neurocognitive status as the empirically derived index of attention and concentration.
PURPOSE: To determine the relative contributions of patient, disease and therapy specific factors on neurocognitive outcome of brain tumorpatients. PATIENTS AND METHODS: Seventy-nine patients (mean age = 41.1 years; range: 17-75 years; 54% male, 46% female) with glioblastoma multiforme (37%), anaplastic astrocytoma (17%), low grade astrocytoma (13%), and oligodendroglioma (10%) predominantly in the frontal regions (45%) were evaluated in an outpatient neuro-oncology clinic. A neuropsychological test battery emphasized elements of attention/concentration. Multiple regression analyses determined relationships between functional outcomes and demographic and clinical predictors. RESULTS: Key predictors of neurocognitive functioning included age of the patient (36-59 years, p < 0.01; >/= 60 years, p < 0.05) and frontal region tumor location (p < 0.01). As expected, older patients did not perform as well as younger patients in absolute terms on neuropsychological tests; decrements persisted when comparisons were based on age-standardized versions of neurocognitive outcomes. Major depressive disorder was marginally associated with outcomes, while surgical interventions and radiotherapy did not show strong associations with test performances. CONCLUSIONS:Primary malignant brain disease was found to be less negative on neurocognitive outcomes for younger than for either middle-aged or older patients. Treatments were not as predictive of neurocognitive outcomes as age. No single test outcome measure was as sensitive to neurocognitive status as the empirically derived index of attention and concentration.
Authors: J A Stehbens; T A Kaleita; R B Noll; W E MacLean; R T O'Brien; M J Waskerwitz; G D Hammond Journal: Neuropsychol Rev Date: 1991-06 Impact factor: 7.444
Authors: M J Taphoorn; A K Schiphorst; F J Snoek; J Lindeboom; J G Wolbers; A B Karim; P C Huijgens; J J Heimans Journal: Ann Neurol Date: 1994-07 Impact factor: 10.422
Authors: K J Murray; D F Nelson; C Scott; A J Fischbach; A Porter; N Farnan; W J Curran Journal: Int J Radiat Oncol Biol Phys Date: 1995-02-01 Impact factor: 7.038
Authors: Y M Archibald; D Lunn; L A Ruttan; D R Macdonald; R F Del Maestro; H W Barr; J H Pexman; B J Fisher; L E Gaspar; J G Cairncross Journal: J Neurosurg Date: 1994-02 Impact factor: 5.115
Authors: Ingeborg Bosma; Maaike J Vos; Jan J Heimans; Martin J B Taphoorn; Neil K Aaronson; Tjeerd J Postma; Henk M van der Ploeg; Martin Muller; W Peter Vandertop; Ben J Slotman; Martin Klein Journal: Neuro Oncol Date: 2006-10-03 Impact factor: 12.300
Authors: Shan S Wong; L Douglas Case; Nancy E Avis; Tiffany L Cummings; Christina K Cramer; Stephen R Rapp Journal: Psychooncology Date: 2019-08-30 Impact factor: 3.894
Authors: Marco Ronald Hassler; Katarzyna Elandt; Matthias Preusser; Johann Lehrner; Petra Binder; Karin Dieckmann; Andrea Rottenfusser; Christine Marosi Journal: J Neurooncol Date: 2009-09-10 Impact factor: 4.130
Authors: Justin Choon Hwee Ng; Angela An Qi See; Ting Yao Ang; Lysia Yan Rong Tan; Beng Ti Ang; Nicolas Kon Kam King Journal: J Neurooncol Date: 2018-11-16 Impact factor: 4.130
Authors: Janet Cohen Sherman; Mary K Colvin; Sarah M Mancuso; Tracy T Batchelor; Kevin S Oh; Jay S Loeffler; Beow Y Yeap; Helen A Shih Journal: J Neurooncol Date: 2016-01 Impact factor: 4.130